.jpg)
In a report released today, Jason Mills from Canaccord Genuity reiterated a Buy rating on Irhythm Technologies (NASDAQ: IRTC), with a price target of $80. The company’s shares opened today at $65, close to its 52-week high of $68.07.
According to TipRanks.com, Mills is a top 25 analyst with an average return of 24.0% and a 78.0% success rate. Mills covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Boston Scientific Corp, and Staar Surgical Company.
Irhythm Technologies has an analyst consensus of Moderate Buy, with a price target consensus of $73.25.
See today’s analyst top recommended stocks >>
Based on Irhythm Technologies’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $28.18 million and GAAP net loss of $11.15 million. In comparison, last year the company earned revenue of $21.44 million and had a GAAP net loss of $5.3 million.
Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
iRhythm Technologies, Inc. is a commercial-stage digital healthcare company, which engages in the development of monitoring and diagnostic solutions for detection of cardiac arrhythmias. It also offers ZIO Service that has proprietary algorithms that distill data from millions of heartbeats into clinically actionable information.
